» Articles » PMID: 29070048

A Framework for the Design, Conduct and Interpretation of Randomised Controlled Trials in the Presence of Treatment Changes

Overview
Journal Trials
Publisher Biomed Central
Date 2017 Oct 27
PMID 29070048
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: When a randomised trial is subject to deviations from randomised treatment, analysis according to intention-to-treat does not estimate two important quantities: relative treatment efficacy and effectiveness in a setting different from that in the trial. Even in trials of a predominantly pragmatic nature, there may be numerous reasons to consider the extent, and impact on analysis, of such deviations from protocol. Simple methods such as per-protocol or as-treated analyses, which exclude or censor patients on the basis of their adherence, usually introduce selection and confounding biases. However, there exist appropriate causal estimation methods which seek to overcome these inherent biases, but these methods remain relatively unfamiliar and are rarely implemented in trials.

Methods: This paper demonstrates when it may be of interest to look beyond intention-to-treat analysis for answers to alternative causal research questions through illustrative case studies. We seek to guide trialists on how to handle treatment changes in the design, conduct and planning the analysis of a trial; these changes may be planned or unplanned, and may or may not be permitted in the protocol. We highlight issues that must be considered at the trial planning stage relating to: the definition of nonadherence and the causal research question of interest, trial design, data collection, monitoring, statistical analysis and sample size.

Results And Conclusions: During trial planning, trialists should define their causal research questions of interest, anticipate the likely extent of treatment changes and use these to inform trial design, including the extent of data collection and data monitoring. A series of concise recommendations is presented to guide trialists when considering undertaking causal analyses.

Citing Articles

Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT.

Mouncey P, Richards-Belle A, Thomas K, Harrison D, Zia Sadique M, Grieve R Health Technol Assess. 2021; 25(14):1-90.

PMID: 33648623 PMC: 7957458. DOI: 10.3310/hta25140.


Current approaches to handling rescue medication in asthma and eczema randomized controlled trials are inadequate: a systematic review.

Chis Ster A, Cornelius V, Cro S J Clin Epidemiol. 2020; 125:148-157.

PMID: 32504781 PMC: 7482905. DOI: 10.1016/j.jclinepi.2020.05.027.


Usage Metrics of Web-Based Interventions Evaluated in Randomized Controlled Trials: Systematic Review.

Koneska E, Appelbe D, Williamson P, Dodd S J Med Internet Res. 2020; 22(4):e15474.

PMID: 32297870 PMC: 7193439. DOI: 10.2196/15474.


Systematic review of statistical methods for safety data in malaria chemoprevention in pregnancy trials.

Patson N, Mukaka M, Otwombe K, Kazembe L, Mathanga D, Mwapasa V Malar J. 2020; 19(1):119.

PMID: 32197619 PMC: 7085184. DOI: 10.1186/s12936-020-03190-z.


How the EMERGE guideline on medication adherence can improve the quality of clinical trials.

Eliasson L, Clifford S, Mulick A, Jackson C, Vrijens B Br J Clin Pharmacol. 2020; 86(4):687-697.

PMID: 32034923 PMC: 7098872. DOI: 10.1111/bcp.14240.


References
1.
Dusing R, Lottermoser K, Mengden T . Compliance with drug therapy-new answers to an old question. Nephrol Dial Transplant. 2001; 16(7):1317-21. DOI: 10.1093/ndt/16.7.1317. View

2.
Shortreed S, Moodie E . Estimating the optimal dynamic antipsychotic treatment regime: Evidence from the sequential multiple assignment randomized CATIE Schizophrenia Study. J R Stat Soc Ser C Appl Stat. 2012; 61(4):577-599. PMC: 3475611. DOI: 10.1111/j.1467-9876.2012.01041.x. View

3.
Snapinn S, Jiang Q, Iglewicz B . Informative noncompliance in endpoint trials. Curr Control Trials Cardiovasc Med. 2004; 5(1):5. PMC: 469444. DOI: 10.1186/1468-6708-5-5. View

4.
Marson A, Al-Kharusi A, Alwaidh M, Appleton R, Baker G, Chadwick D . The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369(9566):1016-26. PMC: 2039891. DOI: 10.1016/S0140-6736(07)60461-9. View

5.
Sheiner L, Rubin D . Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995; 57(1):6-15. DOI: 10.1016/0009-9236(95)90260-0. View